biostudies-literatureUnknown329(8)Chen HS<h4>Importance</h4>Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.<h4>Objective</h4>To assess the efficacy of argatroban plus alteplase for AIS.<h4>Design, setting, and participants</h4>This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.<h4>Interventions</h4>Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatroJAMA640-650https://www.ebi.ac.uk/biostudies/studies/S-EPMC9912168biostudies-literatureEffect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.PMC9912168Shen LWang WZChen HSWang DLiu XWYu MZDuan YJPeng ZLWang KGeng SMWang LHLi GHHuang SMZhu RXWang HJZhou ZHLi HWang LQWang DLARAIS InvestigatorsWang LYMa GBWang YLYang KHWang YSLiu XDChen SHCao YJYang WHJiang CHSun YLYu MLiu LZou MZhou QDLi RHWang EQWu SFZhang SYJiang ZDai YJWang JHZhao LWFeng YFChen ZLWang RXYang HPYuan ZMWang FYCui YZhang YZhang ZHZou RLWen GQYang QCHu LLfalseEffect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.<h4>Importance</h4>Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.<h4>Objective</h4>To assess the efficacy of argatroban plus alteplase for AIS.<h4>Design, setting, and participants</h4>This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.<h4>Interventions</h4>Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatro2023-01-01T00:00:00Z2023 Feb2026-07-14T19:57:11.106Z2025-02-19T01:18:08.496ZS-EPMC99121683675775510.1001/jama.2023.0550